Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has presented updates from a Phase I clinical trial for its tetravalent bispecific antibody (BsAb), FS222, at the American Society of Clinical Oncology (ASCO) annual meeting. The study focuses on the use of FS222 in treating advanced solid tumors as a monotherapy.
FS222 combines a CD137 (4-1BB) agonist with a PD-L1 inhibitor, representing a novel approach to cancer treatment. The first-in-human, dose-escalation Phase I trial has enrolled 100 patients, aiming to evaluate the drug’s safety profile and establish the maximum tolerated dose. Additional study objectives include assessing anti-tumor activity, pharmacokinetics, and pharmacodynamics.- Flcube.com
